Patents Examined by Ganapathirama Raghu
  • Patent number: 11400143
    Abstract: Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 2, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Jan P. Kraus, Tomas Majtan, Erez Bublil
  • Patent number: 11396668
    Abstract: A method of demethylizing an opioid to a nor-opioid is provided. The method comprises contacting an opioid with at least one enzyme. Contacting the opioid with the at least one enzyme converts the opioid to a nor-opioid. A method of converting a nor-opioid to a nal-opioid is provided. The method comprises contacting a nor-opioid with at least one enzyme. Contacting the nor-opioid with the at least one enzyme converts the nor-opioid to a nal-opioid.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: July 26, 2022
    Assignee: Antheia, Inc.
    Inventors: Christina D. Smolke, Catherine Thodey, Isis Trenchard
  • Patent number: 11396669
    Abstract: The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: July 26, 2022
    Assignee: Evolva SA
    Inventors: Jon Heal, Philipp Berninger, Kim Olsson, Joe Sheridan, Laura Occhipinti, Laura Brembati, Christian Nyffenegger, Christophe Folly
  • Patent number: 11384371
    Abstract: The use of a cytochrome P-450 enzyme comprising SEQ ID NO: 3, or a variant enzyme having at least 70% identity thereto and having CYP-450 activity, for the hydroxylation of an organic compound.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 12, 2022
    Assignee: HYPHA DISCOVERY LIMITED
    Inventors: Jonathan Charles Paul Steele, Antonio De Riso, Headley St Edward Williams, Richard Kerry Phipps, Stephen Keith Wrigley, Kinga Linda Nytko, Vincent Poon, Sebastian Schulz, John Maxim Ward
  • Patent number: 11384373
    Abstract: To provide a method for industrially producing a sugar carboxylic acid from an oxidized starch decomposition product or oxidized transfer reaction product having a degree of polymerization of 2 or more in a high yield, using a catalase formulation which quickly decomposes hydrogen peroxide produced as a by-product in the oxidation.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: July 12, 2022
    Inventor: Ken Fukami
  • Patent number: 11384347
    Abstract: The present invention relates to alpha-amylase variants comprising substitutions at positions corresponding to positions 268 and 293 of SEQ ID NO: 1, in particular substitutions selected from the group consisting of: 268G+293Y; 268G+293F; 268G+293W; 268G+293H; 268G+293A; 268G+293Q; 268A+293Y; 268A+293F; 268A+293W; 268A+293H; 268A+293A; 268A+293Q; 268P+293Y; 268P+293F; 268P+293W; 268P+293H; 268P+293A; 268P+293Q; 268S+293Y; 268S+293F; 268S+293W; 268S+293H; 268S+293A; 268S+293Q; 268T+293Y; 268T+293F; 268T+293W; 268T+293H; 268T+293A; 268T+293Q; 268V+293Y; 268V+293F; 268V+293W; 268V+293H; 268V+293A; 268V+293Q; 268I+293Y; 268I+293F; 268I+293W; 268I+293H; 268I+293A; 268I+293Q; 268L+293Y; 268L+293F; 268L+293W; 268L+293H; 268L+293A; 268L+293Q; 268M+293Y; 268M+293F; 268M+293W; 268M+293H; 268M+293A; 268M+293Q; and wherein the variant has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to a
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: July 12, 2022
    Assignee: NOVOZYMES A/S
    Inventors: Carsten Andersen, Lars Giger, Johanne Mørch Jensen, Louis Patrick Lessard
  • Patent number: 11377463
    Abstract: A new class of sucrose esters and a method for their preparation is described herein.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: July 5, 2022
    Assignee: Julius-Maximilians-Universitaet Wuerzburg
    Inventors: Christian Possiel, Juergen Seibel
  • Patent number: 11371032
    Abstract: The present invention discloses a polypeptide having beta-glucosidase activity. The activity is retained also in high glucose concentration. The invention also discloses an isolated polynucleotide, a nucleic acid construct and a recombinant host usable in production of said polypeptide, and a method for producing the polypeptide. Further the invention discloses compositions including the polypeptide and method of using the polypeptide in hydrolysis or synthesis.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: June 28, 2022
    Assignee: Teknologian Tutkimuskeskus VTT Oy
    Inventors: Kaisa Marjamaa, Anu Koivula, Nina Aro, Tiina Pakula
  • Patent number: 11365402
    Abstract: Provided herein are substantially non-luminescent peptide/polypeptide tags that are inserted internally within a protein of interest or between N-terminal and C-terminal peptides/polypeptides. Interaction of the internally-inserted tag with a complement polypeptide/peptide that is also substantially non-luminescent results in the formation a bioluminescent reporter complex.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: June 21, 2022
    Assignee: Promega Corporation
    Inventors: Andrew S. Dixon, Lance P. Encell, Thomas Machleidt, Marie Schwinn, Keith Wood, Monika Wood, Kris Zimmerman
  • Patent number: 11365431
    Abstract: The present invention provides for a genetically modified yeast cell comprising at least six or more of the following modifications: increased expression of Mus musculus fatty acid reductase, acetyl-CoA carboxylase, fatty acid synthase 1, fatty acid synthase 2, a mutant of the bottleneck enzyme encoded by ACC1 insensitive to post-transcriptional and post-translational repression, and/or a desaturase encoded by OLE1, and reduced expression of DGA1, HFD1, ADH6, and/or GDH1. The present invention provides a method for constructing the genetically modified yeast cell, and a method for producing a fatty alcohol from the genetically modified yeast cell.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: June 21, 2022
    Assignee: The Regents of the University of California
    Inventors: Leopold D'Espaux, Jay D. Keasling
  • Patent number: 11365375
    Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: June 21, 2022
    Assignee: NOVOZYMES A/S
    Inventors: Carsten Andersen, Vivek Srivastava, Padmavathi Balumuri, Partha Pratim Chakrabarti, Sohel Dalal
  • Patent number: 11359220
    Abstract: A saccharification reaction mixture wherein the reaction mixture can saccharify at least one of cellulose and hemicellulose and contains at least one of cellulose and hemicellulose, a saccharification enzyme, silica or a silica-containing substance, and at least one compound (A) selected from the group including a polyhydric alcohol compound represented by the following formula (1) or a derivative thereof and an acetylene glycol represented by formula (2) or an alkylene oxide adduct thereof. The symbols in the chemical formulas are defined in the specification.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: June 14, 2022
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Kazutoshi Odaka, Kazutoshi Sekiguchi
  • Patent number: 11359216
    Abstract: The disclosure relates to fatty diols and recombinant microorganisms for producing them. More particularly, the disclosure relates to recombinant microorganisms engineered to produce fatty diols via fermentation. Further encompassed is a process that uses the microorganisms to produce fatty diols from a simple carbon source.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: June 14, 2022
    Assignee: Genomatica, Inc.
    Inventors: Andreas W. Schirmer, Noah Helman, Haibo Wang, Zhihao Hu, Vikranth Arlagadda, Alma Itzel Ramos-Solis, Elizabeth Clarke
  • Patent number: 11339383
    Abstract: The invention provides a mutant of a parent heterotrimeric G protein alpha (G?) subunit, which mutant (i) lacks at least one helix of the helical domain of the parent G? subunit; (ii) is capable of binding to a GPCR in the absence of a heterotrimeric G protein beta (G?) subunit and a heterotrimeric G protein gamma (G?) subunit; and (iii) has an amino acid sequence that contains one or more mutations compared to the amino acid sequence of the parent heterotrimeric G? subunit, which mutations are selected from a deletion, a substitution and an insertion.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: May 24, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Byron Carpenter, Andrew Leslie, Rony Nehmé, Christopher Gordon Tate, Antony Warne
  • Patent number: 11332770
    Abstract: The present disclosure relates to a method for preparing a transfructosylated steviol glycoside using Arthrobacter-derived microorganisms, a culture thereof, a supernatant of the culture, an extract of the culture, and a lysate of the microorganisms.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: May 17, 2022
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Tae Joo Yang, In Sung Kang, Min Hoe Kim, Sunghee Park, Sun Chu, Seong Bo Kim, Young Mi Lee, Young Su Lee, Eun Jung Choi
  • Patent number: 11332765
    Abstract: A method of increasing terpenoid production in a host cell that produces one or more terpenoids, comprising: a) providing a host cell that produces one or more terpenoids, said host cell comprising a vector comprising a polynucleotide sequence encoding a terpene synthase enzyme; b) modifying the vector to: i. introduce an inducible promoter operably linked to the polynucleotide sequence encoding the terpene synthase enzyme; and ii. introduce a polynucleotide sequence encoding a ribosomal binding site (RBS) that increases translation initiation rate of the terpenoid compared to a wild type ribosomal binding site; c) determining the dosage of an inducer capable of inducing the inducible promoter; d) culturing the host cell in a culture medium in the presence of the inducer at the dosage determined from step c); and e) isolating the terpenoid from the culture medium.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: May 17, 2022
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Congqiang Zhang, Xixian Chen, Sudha Shukal
  • Patent number: 11324235
    Abstract: The invention relates to a polypeptide for the hydrolytic cleavage of zearalenone and/or at least one zearalenone derivative, said polypeptide being a hydrolase having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-15 or a functional variant thereof, wherein the sequence of the functional variant is at least 40% identical to at least one of the amino acid sequences. The invention also relates to: an additive containing the polypeptide; an isolated polynucleotide that encodes the polypeptide; and a method for the hydrolytic cleavage of zearalenone and/or of at least one zearalenone derivative using the polypeptide.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: May 10, 2022
    Assignee: ERBER AKTIENGSELLSCHAFT
    Inventors: Sebastian Fruhauf, Michaela Thamhesl, Martin Pfeffer, Dieter Moll, Gerd Schatzmayr, Eva Maria Binder
  • Patent number: 11326153
    Abstract: The present invention relates to alpha-amylase variants comprising a substitution at a position corresponding to position 188 and at least one further substitution at a position corresponding to position 242 or 279 or 275 of SEQ ID NO: 1, in particular one or more combinations of substitutions selected from the group consisting of E188P+S242Y, E188P+S242F, E188P+S242H, E188P+S242W, E188P+S242P, E188P+S242I, E188P+S242T, E188P+S242L, E188P+K279W, E188P+K279Y, E188P+K279F, E188P+K279H, E188P+K279I, E188P+K279L, E188P+K279D, E188P+K279M, E188P+K279S, E188P+K279T E188P+K279N, E188P+K279Q, E188P+K279V, E188P+K279A, E188P+N275F, E188P+N275Y, E188P+N275W, and E188P+N275H, wherein the variant has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to a parent alpha amylase selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: May 10, 2022
    Assignee: NOVOZYMES A/S
    Inventors: Carsten Andersen, Vasudeva Prahlada Rao, Rakhi Saikia, Vivek Srivastava, Kendra Darlene Stallings
  • Patent number: 11326174
    Abstract: The present invention relates to materials and methods for the production of ethanol. More particularly, the present invention provides genetically modified strains of Saccharomyces cerevisiae exhibiting decreased level of BCY1 protein activity and capable of anaerobic fermentation of xylose into ethanol without the need for cell growth. Also provided are methods of using such genetically engineered yeast strains for improved anaerobic xylose fermentation in the yeast for industrial-scale production of various fuels, chemical feedstocks, and synthetic polymers.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: May 10, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Kevin S Myers, Audrey P Gasch
  • Patent number: 11324811
    Abstract: The present invention provides a method of PEGylating a human truncated cystathionine ?-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: May 10, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, TRAVERE THERAPEUTICS SWITZERLAND GMBH
    Inventors: Tomas Majtan, Jan P. Kraus, Erez M. Bublil, Frank Glavin, Marcia Sellos-Moura